- Home
- XAIR vs BCAB Comparison
XAIR vs BCAB Comparison
Compare XAIR & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | BCAB |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 6.4M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XAIR | BCAB |
|---|---|---|
| Price | $0.37 | $3.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 204.8K | 36.6K |
| Earning Date | 06-16-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.09 | 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,705,000.00 | $300,000.00 |
| Revenue This Year | $122.00 | N/A |
| Revenue Next Year | $58.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 219.67 | N/A |
| 52 Week Low | $0.15 | $0.12 |
| 52 Week High | $3.78 | $6.52 |
Technical Indicators
Market Signals| Indicator | XAIR | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.55 | 44.25 |
| Support Level | N/A | $3.19 |
| Resistance Level | $0.59 | $5.18 |
| Average True Range (ATR) | 0.04 | 0.32 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 17.09 | 35.00 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.